The Charlie Sheen effect on HIV prevention

February 22, 2016

SAN DIEGO, Calif. (Feb. 22, 2016) -- On November 17, 2015 actor Charlie Sheen on NBC's Today Show publicly disclosed he was human immunodeficiency virus (HIV)-positive.

For some time scientists and advocates have recognized the importance of celebrity in public health. Could Sheen's disclosure, albeit tragic, generate renewed national attention for HIV and HIV prevention, providing an important public health benefit?

New research led by San Diego State University Graduate School of Public Health research professor, John W. Ayers -- just published by the Journal of the American Medical Association (JAMA) Internal Medicine finds there were record highs of domestic news coverage of HIV and Google searches for information about HIV and HIV prevention following Charlie Sheen's disclosure.

"Charlie Sheen's disclosure was a potential earth shaking event for HIV prevention in the United States," Ayers said.

Identifying trends

The team relied on public archives for news media trends using the Bloomberg Terminal and Google Trends to describe HIV and HIV prevention engagement since 2004.

Focusing on the hours after Sheen's disclosure, the team monitored news reports mentioning HIV and Google searches originating from the United States broken into four categories: HIV (all searches with "HIV"), condoms (all searches with "condom" or "condoms"), HIV symptomology (all searches with "symptom," "symptoms" or "signs of" and "HIV"), and HIV testing (all searches with "test," "tests," or "testing" and "HIV").

"This big data strategy allowed us to provide a formative assessment of the potential impacts of Charlie Sheen's HIV-positive disclosure at no cost," said Benjamin Althouse, a research scientist at the Institute for Disease Modeling and the Santa Fe Institute, and data architect of the study. "We can directly assess the diffusion of media in the population and how the population is seeking out information based on the timing and content of their Google searches."

The day of Sheen's disclosure coincided with a 265 percent increase in news reports mentioning HIV (97 percent of which also mentioned Sheen) archived on the Bloomberg Terminal, even though HIV-related news reports have been in historic decline. An additional 6,500 stories were reported on Google News alone. This placed Sheen's disclosure among the top 1 percent of historic HIV-related media events.

Sheen's disclosure also corresponded with the greatest number of HIV-related Google searches ever recorded in the United States on a single day. About 2.75 million more Google searches than expected, based on previous trends, included the term HIV on the day of Sheen's disclosure, with 1.25 million more searches than expected including terms for condoms, HIV symptoms, or HIV testing; after adjusting for changes in overall search volume and historic trends.

In relative terms, all HIV searches were 417 percent higher than expected the day of Sheen's disclosure. Condom searches (such as "buy condoms") increased 75 percent. HIV symptom (such as "signs of HIV") and HIV testing (such as "find HIV testing") searches increased 540 and 214 percent, respectively, the day of Sheen's disclosure and remained higher for three days.

A public health challenge

"While no one should be forced to reveal their HIV status and all diagnoses are tragic, Sheen's disclosure may benefit public health by potentially helping many learn more about HIV and HIV prevention," Ayers said.

This potential comes on the heels of historic declines in domestic HIV awareness and prevention. Just two weeks before Sheen's disclosure Tom Frieden, director of the Centers for Disease Control and Prevention, publicly bemoaned the state of domestic HIV control. Of the more than 1.2 million people in the United States living with HIV, nearly one in eight are unaware of their HIV-positive status.

"Sheen's disclosure could be an important event to immediately raise public consciousness around HIV, and make public health messages about HIV that much more salient," said Seth Noar, University of North Carolina professor, an expert on HIV prevention media campaigns and coauthor of the study.

"Celebrity disclosures are not new to HIV, with Rock Hudson and Magic Johnson serving as noteworthy examples. Yet, Sheen's disclosure could be different," said Eric Leas, a student of health communication at the University of California San Diego and study coauthor. "The Web 2.0 era may heighten the impact of Sheen," added Leas.

"With Sheen, unlike with Magic Johnson for instance, we have smartphones in our pockets that we can easily use to learn about HIV within seconds with a single search or click," Leas said.

"At the same time, social media can expand the effect of Sheen's disclosure beyond the initial television broadcast as networks form around celebrities."

"Sadly, the public health community may be missing the mark," Ayers added. "I'm unaware of any major HIV educational campaigns that are using Sheen's disclosure for public health outreach."

"Sheen is a controversial figure and it's incredibly hard to frame public health messages around a figure whose behavior, not unlike any non-celebrity or myself, may at times conflict with public health science," said Ayers.

Controversy itself merits additional study to stay ahead of public debate, according to Mark Dredze, research scientist with Bloomberg LP, assistant research professor at Johns Hopkins University, and study coauthor. "Public health can use and expand our approach to further monitor HIV-related trends and be responsive to these changes in near real-time."

Still, the team notes that Sheen's disclosure has already produced tremendous public health benefits. "More must be done to make the Charlie Sheen effect larger and lasting," Ayers concluded.
-end-


San Diego State University

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.